Titan Pharmaceuticals, Inc. (TTNP) financial statements (2021 and earlier)

Company profile

Business Address 400 OYSTER POINT BLVD
SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5598148
Cash and cash equivalents5598148
Receivables112044
Inventory, net of allowances, customer advances and progress billings011   
Inventory011   
Disposal group, including discontinued operation0     
Other undisclosed current assets111100
Total current assets:781381812
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment111111
Total noncurrent assets:111111
TOTAL ASSETS:8101491913
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities222144
Accounts payable112134
Accrued liabilities011010
Deferred revenue 1
Debt0013  
Disposal group, including discontinued operation2     
Other undisclosed current liabilities001000
Total current liabilities:443455
Noncurrent Liabilities
Long-term debt and lease obligation0444  
Long-term debt, excluding current maturities0444  
Operating lease, liability 0
Liabilities, other than long-term debt  0   
Derivative instruments and hedges, liabilities  0   
Other undisclosed noncurrent liabilities 0  11
Total noncurrent liabilities:044411
Total liabilities:587856
Stockholders' equity
Stockholders' equity attributable to parent4171137
Common stock000298298298
Additional paid in capital371350339262423
Accumulated deficit(367)(349)(333)(323)(309)(314)
Total stockholders' equity:4171137
TOTAL LIABILITIES AND EQUITY:8101491913

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues5470152
Revenue, net0152
Cost of revenue
(Cost of Goods and Services Sold)
(0)(1)(1)   
Gross profit:4260152
Operating expenses(12)(19)(15)(15)(11)(8)
Other undisclosed operating income  1   
Operating income (loss):(7)(17)(8)(15)4(7)
Nonoperating income (expense)(0)0(1)01(5)
Other nonoperating income (expense)(0)0(0)(0)(0)(0)
Interest and debt expense(0)0 11 
Net income (loss):(7)(16)(9)(14)6(11)
Other undisclosed net loss attributable to parent(11)(0) (1)(1) 
Net income (loss) attributable to parent:(18)(16)(9)(14)5(11)
Other undisclosed net loss available to common stockholders, basic  (0)   
Net income (loss) available to common stockholders, basic:(18)(16)(9)(14)5(11)
Other undisclosed net loss available to common stockholders, diluted  (0)(1)(1) 
Net income (loss) available to common stockholders, diluted:(18)(16)(9)(15)4(11)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(7)(16)(9)(14)6(11)
Comprehensive income (loss):(7)(16)(9)(14)6(11)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  1828(1)23
Comprehensive income (loss), net of tax, attributable to parent:(7)(16)914511

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: